Harvard diabetes researcher retracts third paper

A prominent diabetes researcher based at Harvard Medical School has retracted a third paper, citing manipulation of multiple figures.

Late last year, Carl Ronald Kahn—also chief academic officer at Joslin Diabetes Center—retracted two papers for similar reasons. In November, Kahn pulled a 2005 paper from The Journal of Clinical Investigation (JCI) and a month later, he retracted a 2003 paper from The Journal of Biological Chemistry (JBC), both times citing duplications that the authors said were introduced while assembling the figures.

Last month, Kahn retracted his third paper, also published in JBC in 2003, because the authors omitted data when constructing the images. Still, the authors remain confident in their findings, given that data from other labs “have confirmed and extended the conclusions of the manuscript.”

Here’s the retraction notice: Continue reading Harvard diabetes researcher retracts third paper

“Existence and motive to retaliate:” Judge hands victory to whistleblower scientist

A Michigan researcher whose accusations of misconduct against his former employers led to years of legal battles has won a judge’s ruling that could earn him one of his jobs back.

Over the past few years, Christian Kreipke has been embroiled in legal battles with the Detroit VA Medical Center and Wayne State University, where he held a dual appointment. In 2010, Kreipke accused Wayne State of misusing federal funds — then was fired in 2012 when the university brought its own case of research misconduct against him. In 2013, the VA followed suit. In 2014, Kreipke lost a whistleblower lawsuit against the university. As a result of the Wayne State investigation, journals have retracted five of his papers, some as recently as last month.

In March, a judge ordered the Department of Veterans Affairs to reinstate Kreipke’s position, among other requests.  Continue reading “Existence and motive to retaliate:” Judge hands victory to whistleblower scientist

Plant biologist earns string of retractions, bringing total to 9

A pair of plant biologists has lost a string of papers over concerns about image manipulation. One author has added eight new retractions to his CV; the other has added five.

Last summer, a journal retracted another paper by the pair, also citing suspicions of image manipulation. The latest batch of retractions — issued by seven different journals — includes some papers that have been questioned on PubPeer.

Dibyendu Talukdar, listed at the University of Calcutta in West Bengal, India, is the sole author on three retracted papers. He shares five new retractions with Tulika Talukdar listed at the University of North Bengal. That brings their totals to nine and six, respectively. (We’re not sure if the Drs. Talukdar are related).

We’ll start with the papers they share: Continue reading Plant biologist earns string of retractions, bringing total to 9

Weekend reads: A “culture of fear?”; blogs vs. academic papers; neurosurgery retractions on the rise

The week at Retraction Watch featured a new record for most retractions by a single journal, and an impassioned plea from a biostatistician for journals to clean up their act. Here’s what was happening elsewhere:  Continue reading Weekend reads: A “culture of fear?”; blogs vs. academic papers; neurosurgery retractions on the rise

Chemist wins injunction against university trying to revoke her degree

A scientist has won an injunction against the University of Texas at Austin, which was deciding whether or not to revoke her PhD.

We’ve been covering the case of Suvi Orr, a chemist now based at Pfizer who earned a PhD in 2008, for a few years. During that time, UT has tried to revoke her degree twice, after the paper that made up part of her dissertation was retracted in 2012 — for allegedly containing falsified data, according to the school. The university revoked her degree in 2014, then reinstated it after she sued.

Last year, the school tried to revoke it again, prompting Orr to sue for a second time — and ask for more than $95,000 in legal fees and expenses.

In a decision released April 20, a Texas Court of Appeals has upheld Orr’s request for an injunction against UT, preventing it from deciding whether to revoke her degree. Specifically, Orr asked that UT not be allowed to make a decision until the court has weighed in on a separate appeal, in which Orr argues the university doesn’t have the right to revoke her degree.

According to her lawyer, David Sergi:

Continue reading Chemist wins injunction against university trying to revoke her degree

Dear journals: Clean up your act. Regards, Concerned Biostatistician

Romain-Daniel Gosselin

Recently, a biostatistician sent an open letter to editors of 10 major science journals, urging them to pay more attention to common statistical problems with papers. Specifically, Romain-Daniel Gosselin, Founder and CEO of Biotelligences, which trains researchers in biostatistics, counted how many of 10 recent papers in each of the 10 journals contained two common problems: omitting the sample size used in experiments, as well as the tests used as part of the statistical analyses. (Short answer: Too many.) Below, we have reproduced his letter.

Dear Editors and Colleagues,

I write this letter as a biologist and instructor of biostatistics, concerned about the disregard for statistical reporting that is threatening scientific reproducibility. I hereby urge you to spearhead the strict application of existing guidelines on statistical reporting. Continue reading Dear journals: Clean up your act. Regards, Concerned Biostatistician

Job alert: Biology society hiring editors to screen images

A biology society is hiring three editors to screen images in submissions to its journal, Journal of Biological Chemistry — which we think is a great idea.

We don’t typically mention job ads on our site, except when they become relevant to cleaning up the literature — and with the latest job ad, the JBC joins the ranks of other journals that have taken a proactive stance against image problems, including manipulation. The publisher, American Society for Biochemistry and Molecular Biology (ASBMB), plans to hire three “Technical Image Editors,” which will screen the images contained within the thousands of papers the journal publishes each year, many of which contain multiple panels and supplemental data.

Kaoru Sakabe, Data Integrity Manager at ASBMB, told us:

Continue reading Job alert: Biology society hiring editors to screen images

“Ethical ambiguity:” When scientific misconduct isn’t black and white

David Johnson
Elaine Howard Ecklund

Some types of misconduct are obvious – most researchers would agree cooking data and plagiarizing someone’s work are clear no-nos. But what about overhyping your findings? Using funding allocated to an unrelated project, if it keeps a promising young student afloat? On these so-called “gray” areas of research behavior, people aren’t so clear what to do. A few years ago, David R. Johnson at the University of Nevada Reno and Elaine Howard Ecklund at Rice University interviewed hundreds of physicists; their conclusions appeared recently in Science and Engineering Ethics (and online in 2015).

Retraction Watch: Your paper discusses “ethical ambiguity” – what does that mean? Can you provide examples of such behavior?

Continue reading “Ethical ambiguity:” When scientific misconduct isn’t black and white

A new record: Major publisher retracting more than 100 studies from cancer journal over fake peer reviews

Springer is retracting 107 papers from one journal after discovering they had been accepted with fake peer reviews. Yes, 107.

To submit a fake review, someone (often the author of a paper) either makes up an outside expert to review the paper, or suggests a real researcher — and in both cases, provides a fake email address that comes back to someone who will invariably give the paper a glowing review. In this case, Springer, the publisher of Tumor Biology through 2016, told us that an investigation produced “clear evidence” the reviews were submitted under the names of real researchers with faked emails. Some of the authors may have used a third-party editing service, which may have supplied the reviews. The journal is now published by SAGE.

The retractions follow another sweep by the publisher last year, when Tumor Biology retracted 25 papers for compromised review and other issues, mostly authored by researchers based in Iran. With the latest bunch of retractions, the journal has now retracted the most papers of any other journal indexed by Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters. In 2015, its impact factor — 2.9 — ranked it 104th out of 213 oncology journals.

Here’s more from Springer’s official statement, out today:

Continue reading A new record: Major publisher retracting more than 100 studies from cancer journal over fake peer reviews

“Think of the unthinkable:” JAMA retraction prompts author to urge others to share data

A few months ago, a researcher told Evelien Oostdijk there might be a problem with a 2014 JAMA study she had co-authored.

The study had compared two methods of preventing infection in the intensive care unit (ICU). But a separate analysis had produced different results.

Oostdijk, from the University Medical Center Utrecht in The Netherlands, immediately got to work to try to figure out what was going on. And she soon discovered the problem: The coding for the two interventions had been reversed at one of the 16 ICUs. This switch had “a major impact on the study outcome,” last author Marc Bonten, also from the University Medical Center Utrecht, wrote in a blog post about the experience yesterday, because it occurred at “one of the largest participating ICUs.”

When Oostdijk and a researcher not involved in the study analyzed the data again, they discovered a notable difference between the revised and original findings: The new analysis revealed that one of the interventions had a small but significant survival benefit over the other.

Oostdijk and Bonten, who supervised the re-analysis, notified their colleagues of the revised study outcomes and contacted the journal requesting a retraction and replacement, which was published yesterday in JAMA.

According to the notice of retraction and replacement:

Continue reading “Think of the unthinkable:” JAMA retraction prompts author to urge others to share data